PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Mycophenolate Mofetil→

Mycophenolate Mofetil PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
128794-94-5
Molecular formula
C23H31NO7
Molecular weight
433.5 g/mol
Drug class
Antimetabolite immunosuppressantprodrug of mycophenolic acid (MPA)
Mechanism of action
After absorption, mycophenolate mofetil is hydrolysed to mycophenolic acid, a selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This inhibits de-novo guanosine nucleotide synthesis and suppresses proliferation of T and B lymphocytes.
Indications / reported uses
  • Prophylaxis of organ rejection in adult and paediatric recipients aged 3 months and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants; not a stand-alone treatment for graft-versus-host disease or psoriasis

Sources: US DailyMed — Mycophenolate mofetil, updated 14 September 2026 · NLM DailyMed — Mycophenolate mofetil mechanism · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Mycophenolate Mofetil PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Mycophenolate Mofetil Permitted Daily Exposure (PDE) report (the Mycophenolate Mofetil PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Mycophenolate Mofetil Occupational Exposure Limit (OEL) report (the Mycophenolate Mofetil OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.